Fig 1: Silencing PGC-1α significantly suppressed the inhibitory effect of MOR on PA-induced total cholesterol levels in mRTECs. (a) Western blot analysis of PGC-1α, LXR, ABCA1, ABCG1, and ApoE expressions in mRTECs cultured for 36 hours and then exposed to PA (sodium palmitate 50 μM), PA+M (PA 50 μM + MOR 1.0 μM), PA+M+P (PA 50 μM + MOR 1.0 μM + PGC1α‐siRNA), or PA+M+C (PA 50 μM + MOR 1.0 μM + control siRNA). (b) Real-time PCR analysis of PGC-1α and LXR expressions in mRTECs cultured for 24 hours. Real-time PCR analysis of ABCA1, ABCG1, and ApoE expressions in mRTECs cultured for 36 hours. (c) Colorimetric analysis of TC and TG levels in mRTECs cultured with PGC1α-siRNA for 36 hours. Data represent the mean ± SEM (n = 3). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 compared with the PA group; #P < 0.05, ##P < 0.01, and ###P < 0.001 compared with the PA+M+P group.
Fig 2: ccRCC cells are able to absorb FAs or cholesterol and rescue cell death.a CCK8 assay: cells cultured in LFM (fat-free medium) or positive lipid medium (addition of 25 nM oleate, palmitate and stearate) were treated with different doses of SR9243 for 96 h. b CCK8 assay of cells cultured in LFM (lipid-free medium) or 0.75 µg/ml cholesterol for 96 h and then treated with different doses of LXR623. c Triglyceride assay: The intracellular triglyceride contents in the control group, the SR9243 group and the positive lipid medium group after 72 h of treatment with SR9243 (0.1 µm) were measured using a triglyceride kit. d Cholesterol assay: cells were treated with LXR623 (786-O cells, 0.1 µM; ACHN cells, 1 µM) for 72 h, and the intracellular cholesterol contents in the control group, the SR9243 group, and the positive lipid medium group were measured. e The Nile Red assay was used to measure the intracellular lipid contents in the three groups. The three groups were the LFM group, 0.1-µM-SR9243 group and positive lipid medium group. f The cells in the control group, the LXR623 (786-O cells, 0.1 µM; ACHN cells, 1 µM) group and the LXR623 plus cholesterol group were observed under an inverted microscope. g, i Western blotting experiments were performed by adding DMSO, 0.1 µM SR9243, or SR9243 plus positive lipid medium (25 nM oleate, palmitate and stearate) to 786-O cells for 96 h. The protein levels of SREBP-1c, FASN and SCD1 were analysed via immunoblotting. h, j Western blotting experiments were performed by adding DMSO, 0.1 µM LXR623, or LXR623 plus 0.75 µg/ml cholesterol to 786-O cells for 96 h. The protein levels of LDLR and ABCA1 were analysed via immunoblotting
Fig 3: GluA1 expression and AMPA responses are decreased in AAV-ShPpara–transduced cortical cells.(A, B) Cortical cultures transduced with AAV containing an shRNA sequence targeting Ppara (AAV-ShPpara). An AAV-scramble shRNA (AAV-ShSc) was used as a control. The cells were immunolabelled for PPARα (red) and MAP2 (blue, neuronal marker). Scale bar, 200 μm. In (A) PPARα quantification in AAV-ShSc or AAV-ShPpara transduced cortical cells. Data are normalized to AAV-ShSc (n = 6 of each analyzed in three independent experiments, *P < 0.05, Mann–Whitney test). (B) Recordings of calcium transients in one representative GFP positive cell (green) transduced with AAV-ShSc or AAV-ShPpara (insets). Scale bar: 5 μm. (C) AMPA-induced calcium fluorescence in AAV-ShSc and AAV-ShPpara cortical cells. Insets: AMPA responses amplitude expressed as ΔF/F0 (AAV-ShSc; n = 104, AAV-ShPpara; n = 108 cells analyzed in three independent experiments, respectively; ***P < 0.001, Mann–Whitney test). (D) Left panel: RT-qPCR analyses of Gria1 and Abca1 mRNA levels in AAV-ShSc or AAV-ShPpara–transduced cells (n = 9 of each analyzed in four independent experiments). Results are expressed as percentage of respective AAV-ShSc (GluA1: ***P < 0.001, Mann–Whitney test, ABCA1: P > 0.05, t test). Middle panel: representative Western blot of corresponding proteins. Right panel: GluA1 and ABCA1/α tubulin ratios. Results are expressed as percentage of respective AAV-ShSc (n = 6 of each analyzed in three independent experiments, ***P < 0.001, t test). Data information: data are presented as mean ± SEM.Source data are available for this figure.
Fig 4: MiR-199a-5p inhibits cholesterol efflux. (A,B) Cholesterol efflux analysis to ApoA1 performed in mouse peritoneal macrophages transfected with Ctrl-miR (CM) and miR-199a-5p or Ctrl-Inh (CI) or Inh-miR-199a-5p and stimulated with or without T0901317 (T090) 3 μm for 12 h. Data are the means ± SEM of three independent experiments in triplicate. *P < 0.05 Ctrl-miR-199a-5p compared with miR-199a-5p or Ctrl-Inh-199 compared with Inh-miR-199a-5p. (A,B) Representative Western blots of ABCA1 in mouse peritoneal macrophages transfected with CM and miR-199a-5p or CI or Inh-miR-199a-5p. HSP90 was used as a loading control.
Fig 5: The expression levels of LXRs and their targets ABCA1 and ABCG1 are lower in macrophages of CNV lesions of Sts-/- mice.(A, B, C, D) Representative images of F4/80 (green) and LXRα (red) (A), LXRβ (red) (B), ABCA1 (red) (C), and ABCG1 (red) (D) staining in flat-mounted RPE–choroid complexes of CNV lesions in WT and Sts-/- mice (n = 5 per group). Scale bar, 100 μm.
Supplier Page from Abcam for Anti-ABCA1 antibody [AB.H10]